Difficulty: Medium
Average Score: 66%
Practice
Which one of the following drugs is most likely to cause hypoglycemia when used as monotherapy in the treatment of type 2 diabetes?
Correct answer
B
Rationale
In the context of CNS stimulants drugs pharmacology, understanding the effects of various medications on glucose metabolism is crucial for safe and effective patient care. In the case of the question regarding which drug is most likely to cause hypoglycemia when used as monotherapy in type 2 diabetes, the correct answer is B) Glipizide.
Glipizide belongs to the class of sulfonylureas, which work by stimulating insulin release from the pancreas. This mechanism of action can lead to an increased risk of hypoglycemia, especially if the patient does not have adequate food intake or experiences increased physical activity.
A) Acarbose is an alpha-glucosidase inhibitor that primarily works by delaying the digestion of carbohydrates, resulting in a gradual rise in blood glucose levels. It does not typically cause hypoglycemia.
C) Metformin is a biguanide that primarily decreases hepatic glucose production and increases peripheral insulin sensitivity. It does not typically cause hypoglycemia when used as monotherapy.
D) Miglitol is also an alpha-glucosidase inhibitor similar to acarbose and does not stimulate insulin release. Therefore, it is not associated with a significant risk of hypoglycemia.
Educationally, it is important for healthcare providers to understand the mechanisms of action of different antidiabetic medications to make informed decisions about treatment regimens and to monitor patients for potential side effects. This knowledge helps in personalizing patient care to ensure optimal outcomes while minimizing risks.
Glipizide belongs to the class of sulfonylureas, which work by stimulating insulin release from the pancreas. This mechanism of action can lead to an increased risk of hypoglycemia, especially if the patient does not have adequate food intake or experiences increased physical activity.
A) Acarbose is an alpha-glucosidase inhibitor that primarily works by delaying the digestion of carbohydrates, resulting in a gradual rise in blood glucose levels. It does not typically cause hypoglycemia.
C) Metformin is a biguanide that primarily decreases hepatic glucose production and increases peripheral insulin sensitivity. It does not typically cause hypoglycemia when used as monotherapy.
D) Miglitol is also an alpha-glucosidase inhibitor similar to acarbose and does not stimulate insulin release. Therefore, it is not associated with a significant risk of hypoglycemia.
Educationally, it is important for healthcare providers to understand the mechanisms of action of different antidiabetic medications to make informed decisions about treatment regimens and to monitor patients for potential side effects. This knowledge helps in personalizing patient care to ensure optimal outcomes while minimizing risks.